<DOC>
	<DOCNO>NCT00810576</DOCNO>
	<brief_summary>Primary Objectives : 1 . To evaluate response rate patient T-cell Non-Hodgkin 's Lymphoma ( NHL ) receive combination vorinostat bortezomib 2 . To evaluate safety tolerability combination vorinostat bortezomib patient relapse refractory T-cell NHL . Secondary Objectives : 1 . To assess overall survival time treatment failure patient T-cell NHL treat combination vorinostat bortezomib . 2 . Correlative study do assess role vorinostat mediate apoptosis along bortezomib synergy . Changes marker expression baseline post treatment correlate patient clinical response .</brief_summary>
	<brief_title>Combination Vorinostat Bortezomib Relapsed Refractory T-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The Study Drugs : Vorinostat design cause chemical change different group protein attach DNA ( genetic material cell ) , may slow growth cancer cell cause cancer cell die . Bortezomib design block protein play role cell function growth . This may cause cancer cell die . Study Drug Administration : If find eligible take part study , Days 1-14 21-day study cycle , take vorinostat . Vorinostat capsule take mouth , 2 time day ( 1 time morning 1 time even ) . The capsule must take food ( within 30 minute meal ) . On Days 1 , 4 , 8 , 11 cycle receive bortezomib needle vein . This take less 1 minute . If begin experience severe intolerable side effect , study drug schedule may stop 2 week . If side effect improve , may able begin receive study drug , low dose bortezomib . The vorinostat dose change . If continue severe intolerable side effect low dose bortezomib , take study . Study Visits : On Day 1 cycle , follow test procedure perform : - You receive vorinostat capsule ( 14-day supply study cycle ) instruction take drug . You instruct return unused vorinostat capsule back study staff end cycle . - Your medical history record , include drug take . - You ask side effect may . - You physical exam . - You neurological exam . On Day 1 , 4 , 8 , 11 cycle , vital sign measure . On Day 8 cycle , blood drawn ( 5 teaspoon ) routine test . On Day 1 every cycle ( Cycles 3 , 5 , 7 , ) , follow test procedure perform : - You CT scan and/or Positron emission tomography ( PET ) scan check status disease . - Blood ( 5 teaspoon ) draw routine test check status disease . - If doctor think necessary , may bone marrow aspirate and/or biopsy . You compute tomography ( CT ) scan and/or PET scan , need , every 2 cycle ( Cycles 2 , 4 , 6 ) , check status disease . Length Study : You receive study drug 6 month ( 8 cycle ) . After 6 month ( 8 cycle ) receive study drug , disease gotten worse become well , may able stay study continue receive study drug . The study drug would continue give dose schedule . The study visit , blood collection , optional biopsy also continue schedule . If disease get bad develop severe intolerable side effect time , take study drug . End-of-Study Visit : If go study treatment reason , end-of-study visit within 4 week last dose study drug start new treatment . At visit , follow test procedure perform : - You physical exam , include measurement vital sign . - You neurological exam . - You ask well able perform normal activity daily live ( performance status evaluation ) . - Blood ( 5 teaspoon ) draw routine test . - You CT scan PET scan check status disease . Follow-Up Visits : After study treatment , contact phone call every 2 month check 5 year . These phone call last 5 minute . Up 40 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Patients must establish diagnosis relapse refractory Tcell NHL Eligible histology include ; Peripheral Tcell lymphoma ( unspecified ) , CD 30 + anaplastic large cell lymphoma ( ALK1 positive ALK1 negative ) , angioimmunoblastic Tcell lymphoma , angiocentric/nasal type T/NKcell lymphoma , intestinal Tcell lymphoma , hepatosplenic gamma delta Tcell lymphoma , subcutaneous panniculitic Tcell lymphoma , transform Mycosis fungoides ; All patient must last one prior system regimen ( radiation therapy qualify systemic treatment ) . 2 . Patients eligible blood marrow transplant receive treatment maximal reduction tumor bulk : A minimum two cycle therapy give cross transplant . 3 . Patients must least one clearcut bidimensionally measurable site physical exam and/or compute tomography : Baseline measurement measurable site evaluation evaluable disease must obtain within four week prior registration study . 4 . Patient may prior radiation therapy localize disease : Therapy must complete last four week enrollment study . 5 . Patient must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 6 . Patients must age 18 year old . 7 . Patients required adequate bone marrow reserve indicate : Absolute neutrophil count ( ANC ) &gt; /= 1000/mm^3 ; Platelets &gt; /= 80,000/mm^3 ; Hemoglobin &gt; /= 8g/dL ; If bone marrow involvement lymphoma minimum level count require ; These value must obtain within two week protocol entry . 8 . Patients must adequate liver function indicate : Bilirubin &lt; /= 1.5 time upper limit normal ( ULN ) ; Alanine transaminase ( ALT ) &lt; /= 2 time ( ULN ) aspartate transaminase ( AST ) &lt; /= 2 time ULN ; These value must obtain within two week protocol entry . 9 . Patients required adequate renal function indicate serum creatinine &lt; /= 2.5 mg/dL ; This value must obtain within two week protocol entry . 10 . Male patient must agree use accepted effective method contraception duration study . 11 . Female patient must willing use two adequate barrier method contraception prevent pregnancy agree abstain heterosexual activity throughout study post menopausal ( free menses &gt; two year surgically sterilize ) . 12 . Female patient childbearing potential must negative serum pregnancy test ( Beta hCG ) within 72 hour receive first dose vorinostat . 13 . Patients must ability able give inform consent . 1 . Patients : Tcell lymphoma skin involvement exclude evidence systemic disease ; Tcell prolymphocytic leukemia ( TPLL ) ; Tcell large granular lymphocytic leukemia ; Primary cutaneous CD30+ disorder : anaplastic large cell lymphoma lymphomatoid papulosis 2 . Patients active Hepatitis B and/or Hepatitis C infection . 3 . Patients know HIV infection exclude : These patient exclude secondary potential target activate Tcells , population patient already risk Tcell depletion , would contraindication therapy . 4 . Patients active infection require specific antiinfective therapy eligible sign infection resolve . 5 . Patients leave ventricular ejection fraction ( LVEF ) &lt; 45 % . 6 . Patients preexist cardiovascular disease require ongoing treatment . This include : Congestive heart failure ; Severe CAD ; Cardiomyopathy ; Uncontrolled cardiac arrhythmia ; Unstable angina pectoris ; Recent MI . 7 . Patients prior exposure either vorinostat ( include HDAC inhibitor except valproic acid ) bortezomib : Patients receive valproic acid ( VPA ) treatment seizure may enrol study , must receive VPA within 30 day study enrollment . 8 . Patients pregnant breastfeeding : Effects treatment fetus young child unknown time . 9 . Patients invasive solid tumor malignancy past five year except nonmelanoma skin cancer cervical carcinoma situ ductal/lobular carcinoma situ breast currently without evidence disease . 10 . Patients undergoing antineoplastic chemotherapy , radiation , hormonal ( exclude contraceptive ) immunotherapy , investigational medication within past four week . Receipt systemic corticosteroid within 7 day study treatment unless patient take continuous dose 10 mg/day prednisone least 1 month . 11 . Patients deep vein thrombosis within three month . 12 . Patients lymphoma involvement CNS . 13 . Patients undergone prior allogenic transplantation : Prior autologous transplantation accept . 14 . Patient concurrent use complementary alternative medicine would confound interpretation toxicity antitumor activity vorinostat and/or bortezomib . 15 . Patient history allergic reaction attributable compound contain boron mannitol . 16 . Patients psychiatric illness and/or social situation would limit compliance study medication requirement . 17 . Patients grade 2 neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Relapsed T-Cell Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Refractory T-Cell Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>T-cell NHL</keyword>
	<keyword>vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>LDP-341</keyword>
	<keyword>MLN341</keyword>
	<keyword>PS-341</keyword>
	<keyword>Peripheral T-cell lymphoma</keyword>
	<keyword>CD 30 + anaplastic large cell lymphoma</keyword>
	<keyword>Angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>Angiocentric/nasal type T/NK-cell lymphoma</keyword>
	<keyword>Intestinal T-cell lymphoma</keyword>
	<keyword>Hepatosplenic gamma delta T-cell lymphoma</keyword>
	<keyword>Subcutaneous panniculitic T-cell lymphoma</keyword>
	<keyword>Transformed Mycosis fungoides</keyword>
</DOC>